- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04503590
Minimally Invasive Micro Sclerostomy: Performance and Safety Evaluation Study
Eligible Glaucoma patients will undergo pre-surgery examination including:
medicines list, blood tests and ECG. On surgery day: intraocular pressure (IOP) will be measured. Then a sub-conjunctival injection of Mitomycin C will be administered .
The Minimally Invasive Micro Sclerostomy (MIMS) procedure is designed to create a drainage channel at the sclera-corneal junction by penetrating through the wall [scleral tissue] . MIMS procedure may be combined with cataract surgery.
Patients will be followed up to 52 weeks post operation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients will have ECG and blood test up to 30 days prior to the MIMS procedure.
Description of MIMS procedure:
on surgery day, intraocular pressure (IOP) will be measured. Then a sub-conjunctival injection of Mitomycin C will be administered .
creating drainage channel at the sclera-corneal junction by penetrating through the wall [scleral tissue]. MIMS procedure may be combined with cataract surgery.
Post-operatively the patient will be treated with dexamethasone-neomycin drops for at least one month.
Patients will be followed up to 52 weeks post operation.
The following measurements will be included:
- Intra Ocular Pressure (IOP)
- Best Corrected Visual Acuity (BCVA)
- Slit Lamp Biomicroscopic evaluation
- Anterior Segment Optical coherence tomography (OCT)
- Fundus Examination
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Yerevan, Armenia, 0048
- S.V.Malayan'S Eye Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥ 18 years
- Primary open-angle glaucoma,pseudoexfoliation glaucoma or pigmentary glaucoma in the study eye
- Optic nerve appearance characteristic of glaucoma in the study eye
- Patient is treated with 0 to 5 hypotensive medications in the study eye
- Unsatisfactory IOP (≥ 21 mmHg) at the screening visit in the study eye
- If cataract is not present - Shaffer grade ≥ III in all four angle quadrants in the study eye
- Subject is able and willing to attend all scheduled follow-up exams
- Subject understands and signs the informed consent
Exclusion Criteria:
- Ocular conditions with a poorer prognosis in the fellow eye than in the study eye
- Closed angle forms of glaucoma in either eye unless scheduled for cataract surgery immediately prior to the MIMS procedure or the study eye is pseudophakic with PCIOL.
- Congenital or developmental glaucoma in either eye
- Other secondary glaucoma (such as neovascular, uveitic, lens-induced, trauma-induced, or glaucoma associated with increased episcleral venous pressure) in the study eye
- Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the study eye
- Subject has history of penetrating keratoplasty (PKP)
- Any previous surgery in the study eye (except for clear corneal cataract surgery) where the conjunctiva is not intact and elastic.
- Any ocular disease or history in study eye such as severe dry eye, active proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and ocular pathology that may interfere with accurate IOP measurements
- Prior surgery for an ab-interno or ab-externo device implanted in or through the Schlemm's canal in the study eye.
- Use of oral hypotensive medication for glaucoma for treatment of the fellow eye
- Best-corrected visual acuity worse than 20/40 (Snellen equivalent) in the fellow eye
- History of idiopathic or autoimmune uveitis in either eye
- Severe trauma in study eye
- Active iris neovascularization, previous cyclodestructive procedure, prior scleral buckling procedure, presence of silicone oil
- Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in study eye
- Aphakia
- Prior vitreoretinal surgery in study eye
- Clinically significant ocular inflammation or infection within 90 days prior to screening
- Unable to discontinue use of blood thinners in accordance with surgeon's standard preoperative instructions
- Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits
- Current participation or participation in another investigational drug or device clinical trial within the last 30 days before screening visit
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Minimally invasive micro sclerostomy (MIMS)
create a drainage channel at the sclera-corneal junction
|
The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction .
The drainage channel is created by a Stainless Steel surgical tool.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure Reduction
Time Frame: 52 weeks
|
Proportion of subjects achieved a 20% or greater reduction in IOP from Baseline on the same or less number of medications
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Intraocular Pressure
Time Frame: 52 weeks
|
Mean change in IOP from baseline
|
52 weeks
|
Adverse Event
Time Frame: 52 weeks
|
Incidence of adverse events related to MIMS® device/procedure, throughout the study follow-up
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on Minimally Invasive Micro Sclerostomy (MIMS)
-
Sanoculis LtdCompleted
-
Sanoculis LtdNot yet recruitingPrimary Open Angle Glaucoma | Open Angle Glaucoma
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Fondazione Poliambulanza Istituto OspedalieroAssistance Publique - Hôpitaux de Paris; King's College Hospital NHS Trust; Fondazione... and other collaboratorsRecruitingNeoplasm Metastasis | Colorectal Neoplasms MalignantItaly, Belgium, France, Germany, Luxembourg, Netherlands, Norway, Russian Federation, Spain, United Kingdom
-
Radboud University Medical CenterDutch Heart Foundation; Penumbra Inc.CompletedIntracerebral Hemorrhage | Surgical Procedures, Minimally InvasiveNetherlands
-
Postgraduate Institute of Dental Sciences RohtakCompleted
-
Osama Mohammad Ali ElDamshetyUnknown
-
University of FloridaCompletedStroke | Atrial FibrillationUnited States
-
Istituto Clinico HumanitasFondazione Umberto VeronesiRecruiting
-
East China University of Science and TechnologyShanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to... and other collaboratorsCompleted